General Information of Drug (ID: DMRQ0SA)

Drug Name
TT-401 Drug Info
Indication
Disease Entry ICD 11 Status REF
Type-2 diabetes 5A11 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMRQ0SA

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Semaglutide DMAGFOD Type-2 diabetes 5A11 Approved [4]
Liraglutide DM3FXPS Non-insulin dependent diabetes 5A11 Approved [5]
Exenatide DMYHBKN Inflammation 1A00-CA43.1 Approved [6]
Dulaglutide DMYXBV3 Type-2 diabetes 5A11 Approved [7]
Lixisenatide DM0QJDC Type-2 diabetes 5A11 Approved [8]
Pramlintide DM0EZ9Q Type-1/2 diabetes 5A10-5A11 Approved [5]
Albiglutide DM1JEGF Type-2 diabetes 5A11 Approved [8]
Tirzepatide DMQNMAT Type 2 diabetes 5A11 Approved [9]
Efpeglenatide DMKA2PI Type-2 diabetes 5A11 Phase 3 [2]
GLP-1 DMR6YH3 Diabetic complication 5A2Y Phase 3 [4]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Glucagon receptor (GCGR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Glucagon recombinant DMFLUTR Hypoglycemia 5A41 Approved [10]
Dasiglucagon DM74SVE Hypoglycemia 5A41 Approved [11]
Retatrutide DM8WU0Q Obesity 5B81 Phase 3 [12]
MK-8521 DMVNAYE Type-2 diabetes 5A11 Phase 2 [2]
LY2944876 DML6XWR Diabetic complication 5A2Y Phase 2 [13]
LGD-6972 DMPL9KG Type-2 diabetes 5A11 Phase 2 [14]
PF-06291874 DMN94QM Type-2 diabetes 5A11 Phase 2 [15]
LY-2409021 DMZOIP4 Type-2 diabetes 5A11 Phase 2 [16]
REMD 477 DM13OVF Type-1 diabetes 5A10 Phase 2 [17]
Efinopegdutide DMAN2V2 Non-alcoholic steatohepatitis DB92.1 Phase 2 [18]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glucagon receptor (GCGR) TT9O6WS GLR_HUMAN Agonist [2]
Glucagon-like peptide 1 receptor (GLP1R) TTVIMDE GLP1R_HUMAN Modulator [3]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035378)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Relationship between systemic cytokines and complement factor H Y402H polymorphism in patients with dry age-related macular degeneration. Am J Ophthalmol. 2013 Dec;156(6):1176-83.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249).
5 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
6 Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. Diabetes TechnolTher. 2009 Jun;11(6):353-9.
7 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
8 GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.Nat Rev Endocrinol.2012 Dec;8(12):728-42.
9 Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021 Jan 23;106(2):388-396.
10 Glucagon receptor expression and glucagon stimulation of ghrelin secretion in rat stomach. Biochem Biophys Res Commun. 2007 Jun 15;357(4):865-70.
11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
12 Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity? Expert Opin Investig Drugs. 2023 May;32(5):355-359.
13 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
14 Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. Curr Diabetes Rev. 2015 March; 11(1): 17-31.
15 Clinical pipeline report, company report or official report of pfizer.
16 Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes. Diabetes Obes Metab. 2015 Apr;17(4):414-22.
17 Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial. Diabetes Obes Metab. 2018 May;20(5):1302-1305.
18 Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. Expert Opin Emerg Drugs. 2021 Sep;26(3):231-243.